Read our Recent Headlines

November 15 Biotech Update

Today is an important day for the sector. We are at very long term support (the 200 week MA) that has rarely been breached (occasionally but never in a sustained.

November 13 Biotech Update

We are getting what I suspect is a dead cat bounce after the trouncing yesterday. The recent lows need to hold but there really seems to be nothing in terms.

November 12 Biotech Update

A rough start to the week. The market just feels heavy and looks like it wants to break through the recent lows. It looked for a little like it wanted.

Opinion: No, The Antibiotics Market Is Not Broken

In light of slow drug launches and disappointing sales, there is a growing chorus of voices saying the antibiotics drug market is broken; that the government must step in to.

November 8 Biotech Update

Not a lot going on but there are a couple of quick points I want to make today. 1. AKAO is having the completely predictable slow antibiotic launch. You will.

November 7 Biotech Update

The midterm elections are over and now we have a couple hour break before the 2020 presidential campaigning begins. The split congress is likely positive for the markets as they.

November 6 Biotech Update

While there are certainly other things happening in the market, I want to focus today on ONCS as I think there are important take aways not only about the data.



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!